https://allsci.com/news/regulatory/ap301-hyperphosphatemia-dialysis-chinas-nmpa/ AllScien 2026-08-07T16:31:47.404147Z China accepts NDA for Alebund's phosphate binder AP301 after Phase III success https://allsci.com/news/regulatory/fda-fast-track-ovarian-cancer-bioinvent-secures/ AllScien 2026-08-07T16:28:01.316068Z BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data https://allsci.com/news/first-in-human-trials/triple-agonist-obesity-neurocrine-launches-for/ AllScien 2026-08-07T16:26:00.345852Z Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study https://allsci.com/news/approvals/benmelstobart-squamous-lung-cancer-cttqs/ AllScien 2026-08-07T16:21:02.020286Z Sino Bio's benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC https://allsci.com/news/licensing-and-partnerships/arcturus-csl-seqirus-settlement-unwinds-usd-43/ AllScien 2026-08-07T16:13:37.918464Z Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership https://allsci.com/news/clinical-trials/bmn-401-discontinued-biomarin-discontinues-after/ AllScien 2026-08-07T16:01:43.595151Z BioMarin drops BMN 401 following unsuccessful pivotal trial